Neuroendocrine tumors: Clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 6, 2012, Pages 724-764

  Kulke, Matthew H ^a,w   Benson III, Al B ^b,w   Bergsland, Emily ^c,w   Berlin, Jordan D ^d,w   Blaszkowsky, Lawrence S ^e,w   Choti, Michael A ^f,x   Clark, Orlo H ^c,x   Doherty, Gerard M ^g,x   Eason, James ^h   Emerson, Lyska ^i,y   Engstrom, Paul F ^j,w   Goldner, Whitney S ^k,z   Heslin, Martin J ^l,x   Kandeel, Fouad ^m,z   Kunz, Pamela L ^n,w   Kuvshinoff II, Boris W ^o,x   Moley, Jeffrey F ^p,x   Pillarisetty, Venu G ^q,x   Saltz, Leonard ^r,w,aa   Schteingart, David E ^g,z,aa   Shah, Manisha H ^s,w   Shibata, Stephen ^m,w   Strosberg, Jonathan R ^t,w   Vauthey, Jean Nicolas ^u,x   White, Rebekah ^v,x   Yao, James C ^u,w   more..

^a Dana Farber Brigham and Women's Cancer Center   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^h UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j FOX CHASE CANCER CENTER   (United States)

^k NEBRASKA MEDICAL CENTER   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁿ STANFORD CANCER INSTITUTE   (United States)

^o ROSWELL PARK CANCER INSTITUTE   (United States)

^p BARNES JEWISH HOSPITAL   (United States)

^q SEATTLE CANCER CARE ALLIANCE   (United States)

^r MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^s OHIO STATE UNIVERSITY   (United States)

^t H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^u UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^v DUKE CANCER INSTITUTE   (United States)

^w City of Hope   (United States)

^x Surgery/Surgical Oncology   (United States)

^y Pathology   (United States)

^z Endocrinology   (United States)

^aa Internal Medicine   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALDOSTERONE; C PEPTIDE; CALCITONIN; CARBOPLATIN; CATECHOLAMINE; CHROMOGRANIN A; CISPLATIN; CYTOKERATIN; DIAZOXIDE; DOPAMINE; DOXORUBICIN; EPLERENONE; ETOPOSIDE; EVEROLIMUS; GLUCAGON; GLUCOSE; KI 67 ANTIGEN; METADRENALIN; MITOTANE; OCTREOTIDE; PANCREAS POLYPEPTIDE; PARATHYROID HORMONE RELATED PROTEIN; PENTETREOTIDE; SOMATOSTATIN; SPIRONOLACTONE; STREPTOZOCIN; SUNITINIB; SYNAPTOPHYSIN; UNINDEXED DRUG;

ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; ANTINEOPLASTIC ACTIVITY; APPENDECTOMY; APPENDIX CANCER; ARTIFICIAL EMBOLISM; BLOOD CELL COUNT; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SCREENING; CARCINOID; CHEMOEMBOLIZATION; CHOLECYSTECTOMY; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PROTOCOL; COLON CANCER; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CUSHING SYNDROME; CYTOREDUCTIVE SURGERY; DIET THERAPY; DOPAMINE BLOOD LEVEL; DUODENUM CANCER; ENDOSCOPIC ECHOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; FUNCTIONAL STATUS; GASTRINOMA; GLUCAGONOMA; GLUCOSE BLOOD LEVEL; HEMICOLECTOMY; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HORMONE URINE LEVEL; HOSPITAL MANAGEMENT; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; INSULINOMA; INTESTINE RESECTION; JEJUNUM CANCER; LUNG NON SMALL CELL CANCER; LYMPHADENECTOMY; METASTASIS; MITOSIS RATE; MULTIMODALITY CANCER THERAPY; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RECTUM CANCER; REVIEW; SPLENECTOMY; STOMACH CANCER; THYMUS CANCER; TUMOR DIFFERENTIATION; TUMOR VOLUME; ARTICLE; CANCER STAGING; CLASSIFICATION; PRACTICE GUIDELINE;

HUMANS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS;

EID: 84863215783     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0075     Document Type: Review

References (158)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
2. Marx S, Spiegel AM, Skarulis MC, et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998;129:484-494. (Pubitemid 28428085)
3. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET protooncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856. (Pubitemid 23216611)
4. Anlauf M, Garbrecht N, Bauersfeld J, et al. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch 2007;451 Suppl 1:S29-38. (Pubitemid 47283381)
5. Larson AM, Hedgire SS, Deshpande V, et al. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet, in press.
6. Jenson RT, Norton JA. Carcinoid tumors and carcinoid syndrome. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Vol 2, ed 6. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:1813-1826.
7. Joynt KE, Moslehi JJ, Baughman KL. Paragangliomas: etiology, presentation, and management. Cardiol Rev 2009;17:159-164.
8. Klimstra DS, Arnold R, Capella C, et al. Neuroendocrine neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC; 2010:322-326.
9. Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 2011;29:2372-2377.
10. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-1092. (Pubitemid 41815799)
11. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401. (Pubitemid 44451313)
12. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20:2633-2642. (Pubitemid 34575635)
13. Pape UF, Jann H, Muller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008;113:256-265.
14. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.
15. Landry CS, Woodall C, Scoggins CR, et al. Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system. Arch Surg 2008;143:664-670; discussion 670.
16. Landry CS, Brock G, Scoggins CR, et al. A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients. Surgery 2008;144:460-466.
17. Landry CS, Brock G, Scoggins CR, et al. A proposed staging system for small bowel carcinoid tumors based on an analysis of 6,380 patients. Am J Surg 2008;196:896-903; discussion 903.
18. Landry CS, Brock G, Scoggins CR, et al. Proposed staging system for colon carcinoid tumors based on an analysis of 2,459 patients. J Am Coll Surg 2008;207:874-881.
19. Landry CS, Brock G, Scoggins CR, et al. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol 2009;16:51-60.
20. Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011;29:3044-3049.
21. Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007;205:558-563. (Pubitemid 47446316)
22. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727-1733.
23. Ballian N, Loeffler AG, Rajamanickam V, et al. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford) 2009;11:422-428.
24. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010;34:300-313.
25. Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord 2010;11:117-126.
26. Pasieka JL, McKinnon JG, Kinnear S, et al. Carcinoid syndrome symposium on treatment modalities for gastrointestinal carcinoid tumours: symposium summary. Can J Surg 2001;44:25-32. (Pubitemid 32163350)
27. Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res 1999;18:133-141. (Pubitemid 29359395)
28. Thorson AH. Studies on carcinoid disease. Acta Med Scand Suppl 1958;334:1-132.
29. Gilligan CJ, Lawton GP, Tang LH, et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995;90:338-352.
30. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966-973. (Pubitemid 39004355)
31. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987;317:1699-1701. (Pubitemid 18024410)
32. Sandor A, Modlin IM. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol 1998;93:422-428. (Pubitemid 29068350)
33. Mullen JT, Savarese DM. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol 2011;104:41-44.
34. Soga J. Carcinoids of the rectum: an evaluation of 1271 reported cases. Surg Today 1997;27:112-119. (Pubitemid 27093279)
35. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
36. Cwikla JB, Buscombe JR, Caplin ME, et al. Diagnostic imaging of carcinoid metastases to the abdomen and pelvis. Med Sci Monit 2004;10(Suppl 3):9-16.
37. Kaltsas G, Rockall A, Papadogias D, et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004;151:15-27. (Pubitemid 39117361)
38. Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2011;12:427-433.
39. Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am 2001;81:527-542. (Pubitemid 32612114)
40. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-229. (Pubitemid 23188540)
41. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-666. (Pubitemid 16055931)
42. Anderson AS, Krauss D, Lang R. Cardiovascular complications of malignant carcinoid disease. Am Heart J 1997;134:693-702. (Pubitemid 27465065)
43. Jacobsen MB, Nitter-Hauge S, Bryde PE, Hanssen LE. Cardiac manifestations in mid-gut carcinoid disease. Eur Heart J 1995;16:263-268.
44. Bhattacharyya S, Toumpanakis C, Chilkunda D, et al. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol 2011;107:1221-1226.
45. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
46. Liu DM, Kennedy A, Turner D, et al. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. Am J Clin Oncol 2009;32:200-215.
47. Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery 1997;122:1147-1154; discussion 1154.
48. Strosberg JR, Weber JM, Choi J, et al. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol, in press.
49. Gates J, Hartnell GG, Stuart KE, Clouse ME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 1999;19:399-414.
50. Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 2000;62(Suppl 1):79-83. (Pubitemid 30665944)
51. Kalinowski M, Dressler M, Konig A, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 2009;79:137-142.
52. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008;31:271-279.
53. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008;113:921-929.
54. Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys, in press.
55. Murthy R, Kamat P, Nunez R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 2008;19:145-151.
56. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008;247:1029-1035. (Pubitemid 351770424)
57. Fazio N, de Braud F, Delle Fave G, Oberg K. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol 2007;18:13-19. (Pubitemid 46152493)
58. Fjallskog ML, Sundin A, Westlin JE, et al. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 2002;19:35-42. (Pubitemid 34587755)
59. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003;90:687-693. (Pubitemid 36760596)
60. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689-2696. (Pubitemid 46606312)
61. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
62. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-4318.
63. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-2012.
64. Parithivel K, Ramaiya N, Jagannathan JP, et al. Everolimus- and temsirolimus-associated enteritis: report of three cases. J Clin Oncol 2010;29:e404-406.
65. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416-2423.
66. Krenning EP, Teunissen JJM, Valkema R, et al. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. J Endocrinol Invest 2005;28:146-150.
67. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3] octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-422. (Pubitemid 36692868)
68. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-2762. (Pubitemid 46179465)
69. Kwekkeboom DJ, Teunissen JJ, Kam BL, et al. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am 2007;21:561-573. (Pubitemid 46843516)
70. Gulenchyn KY, Yao X, Asa SL, et al. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol) 2012;24:294-308.
71. Bonaccorsi-Riani E, Apestegui C, Jouret-Mourin A, et al. Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. Transpl Int 2010;23:668-678.
72. Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011;146:953-958.
73. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 1998;66:1307-1312. (Pubitemid 28551010)
74. Le Treut YG, Gregoire E, Belghiti J, et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 2008;8:1205-1213. (Pubitemid 351763685)
75. Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002;73:386-394. (Pubitemid 34174288)
76. Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-3500. (Pubitemid 350160130)
77. Moore FD, Scoinski MA, Joste NE. Endocrine tumors and malignancies. In: Skarin A, ed. Atlas of Diagnostic Oncology, 3rd ed. Philadelphia, PA: Elsevier Science Limited; 2003.
78. Alexakis N, Neoptolemos JP. Pancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2008;22:183-205.
79. Kulke MH, Bendell J, Kvols L, et al. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 2011;4:29.
80. Bernini GP, Moretti A, Ferdeghini M, et al. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer 2001;84:636-642. (Pubitemid 32238997)
81. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007;25:1967-1973. (Pubitemid 46972778)
82. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004;60:644-652. (Pubitemid 38669857)
83. Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA 1994;271:1429-1435. (Pubitemid 24132490)
84. Rosch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992;326:1721-1726.
85. Doppman JL, Chang R, Fraker DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 1995;123:269-273.
86. Fajans SS, Vinik AI. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am 1989;18:45-74. (Pubitemid 19058101)
87. Comi R, Gordon P, Doppman J. Insulinoma. In: Go VL, Di-Magno EP, Gardner JD, et al., eds. The Pancreas: Biology, Pathology and Disease, 2nd ed. New York, NY: Raven Press; 1993.
88. Creutzfeldt W. Insulinomas: clinical presentation, diagnosis, and advances in management. In: Jensen RT, Mignon M, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Basel, Switzerland: Karger; 1994:148-165.
89. Stehouwer CD, Lems WF, Fischer HR, et al. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh) 1989;121:34-40. (Pubitemid 19167528)
90. Haynes AB, Deshpande V, Ingkakul T, et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg 2011;146:534-538.
91. Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 2007;25:5609-5615.
92. Parekh JR, Wang SC, Bergsland EK, et al. Lymph node sampling rates and predictors of nodal metastases in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas, in press.
93. Strosberg JR, Cheema A, Kvols LK. Stage I nonfunctioning neuroendocrine tumors of the pancreas: surgery or surveillance? [abstract]. J Clin Oncol 2011;29(Suppl 4):Abstract 349.
94. Boninsegna L, Panzuto F, Partelli S, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer, in press.
95. Casadei R, Ricci C, Pezzilli R, et al. Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology 2010;10:33-38.
96. Kim SJ, Kim JW, Oh DY, et al. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung). Am J Clin Oncol, in press.
97. De Jong MC, Farnell MB, Sclabas G, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg 2010;252:142-148.
98. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010;17:3129-3136.
99. Pommier RF, Wolin EM, Panneerselvam A, et al. Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): results from the RADIANT-3 trial [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 4103.
100. Shah MH, Lombard-Bohas C, Ito T, et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 4010.
101. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
102. Raymond E, Niccoli P, Raoul J, et al. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET) [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 4008.
103. Richards CJ, Je Y, Schutz FA, et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 2011;29:3450-3456.
104. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-523.
105. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-4771.
106. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991. (Pubitemid 46849574)
107. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406. (Pubitemid 46630459)
108. Kulke MH, Stuart K, Earle CC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors [abstract]. J Clin Oncol 2006;24(Suppl):Abstract 4044.
109. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-345.
110. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-275.
111. Bloomston M, Muscarella P, Shah MH, et al. Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg 2006;10:1361-1370. (Pubitemid 44908998)
112. Gomez D, Malik HZ, Al-Mukthar A, et al. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) 2007;9:345-351. (Pubitemid 47604634)
113. Pederzoli P, Falconi M, Bonora A, et al. Cytoreductive surgery in advanced endocrine tumours of the pancreas. Ital J Gastroenterol Hepatol 1999;31(Suppl):S207-212. (Pubitemid 29527897)
114. Gurusamy KS, Pamecha V, Sharma D, Davidson BR. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-enteropancreatic neuroendocrine tumours. Cochrane Database Syst Rev 2009;21:CD007118.
115. Strosberg JR, Cheema A, Campos T, et al. Phase II study of sunitinib malate following hepatic artery embolization for metastatic neuroendocrine tumors [abstract]. J Clin Oncol 2011;29(Suppl 4):Abstract 244.
116. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994;116:1111-1116.
117. Mathe Z, Tagkalos E, Paul A, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation 2011;91:575-582.
118. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-2037. (Pubitemid 43854976)
119. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001;25:914-926. (Pubitemid 32666394)
120. Solcia E, Rindi G, Paolotti D, et al. Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. Ann Oncol 1999;10(Suppl 2):S9-15.
121. Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996;119:161-170.
122. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-3155. (Pubitemid 23356754)
123. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002;87:5367-5384. (Pubitemid 36034330)
124. Lynch HT, Radford B, Lynch JF. SBLA syndrome revisited. Oncology 1990;47:75-79. (Pubitemid 20027743)
125. Soon PSH, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 2008;13:548-561. (Pubitemid 351872872)
126. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671. (Pubitemid 33152604)
127. Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer 1993;54:408-410. (Pubitemid 23169678)
128. Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994;78:790-794.
129. Gicquel C, Bertagna X, Schneid H, et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1994;78:1444-1453. (Pubitemid 24181019)
130. Gicquel C, Raffin-Sanson ML, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 1997;82:2559-2565. (Pubitemid 27337873)
131. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003;169:5-11. (Pubitemid 35461537)
132. Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981;71:855-875. (Pubitemid 12192366)
133. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195-1201. (Pubitemid 20137851)
134. Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995;75:2587-2591.
135. Graham PE, Smythe GA, Edwards GA, Lazarus L. Laboratory diagnosis of phaeochromocytoma: which analytes should we measure? Ann Clin Biochem 1993;30(Pt 2):129-134. (Pubitemid 23096588)
136. Peplinski GR, Norton JA. The predictive value of diagnostic tests for pheochromocytoma. Surgery 1994;116:1101-1109.
137. Neary NM, King KS, Pacak K. Drugs and pheochromocytoma - don't be fooled by every elevated metanephrine. N Engl J Med 2011;364:2268-2270.
138. Norton JA, Le HN. Adrenal tumors cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Vol. 2, 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:1770-1780.
139. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-3281.
140. Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol 2004;5:718-726. (Pubitemid 39646780)
141. Shen WT, Sturgeon C, Duh QY. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol 2005;89:186-192. (Pubitemid 40315915)
142. Guignat L, Bertherat J. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective. Eur J Endocrinol 2010;163:9-13.
143. Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002;222:629-633. (Pubitemid 34215205)
144. Boland GW, Lee MJ, Gazelle GS, et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 1998;171:201-204. (Pubitemid 28308675)
145. Chang A, Glazer HS, Lee JK, et al. Adrenal gland: MR imaging. Radiology 1987;163:123-128. (Pubitemid 17043014)
146. Schultz CL, Haaga JR, Fletcher BD, et al. Magnetic resonance imaging of the adrenal glands: a comparison with computed tomography. AJR Am J Roentgenol 1984;143:1235-1240. (Pubitemid 15219832)
147. Dickstein G, Shechner C, Arad E, et al. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998;83:3100-3103. (Pubitemid 28500941)
148. Khorram-Manesh A, Ahlman H, Jansson S, et al. Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg 1998;22:605-611.
149. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993;71:3119-3123. (Pubitemid 23145548)
150. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356:2372-2380. (Pubitemid 46883771)
151. Barzon L, Fallo F, Sonino N, et al. Adrenocortical carcinoma: experience in 45 patients. Oncology 1997;54:490-496. (Pubitemid 27470260)
152. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001;92:1385-1392. (Pubitemid 32947821)
153. Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994;69:947-951. (Pubitemid 24140681)
154. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009;27:4619-4629.
155. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005;12:657-666.
156. Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000;11:1281-1287.
157. First international randomized trial in locally advanced and metastatic adrenocortical carcinoma treatment (FIRM-ACT) etoposide, doxorubicin, cisplatin and mitotane vs streptozotocin and mitotane. Bethesda, MD: National Cancer Institute (NCI); 2011.
158. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol 2011;29:934-943.